1

2
Lücking Ulrich, Siemeister Gerhard, Schäfer Martina, Briem Hans: (De) Makrozyklische pyrimidine, deren herstellung und verwendung als arzneimittel, (En) Macrocyclic pyrimidines, the production thereof and the use of the same as medicaments. Schering Aktiengesellschaft, April 1, 2004: WO/2004/026881 (24 worldwide citation)

(EN) The invention relates to macrocyclic pyrimidine derivatives of general formula (I) -wherein R1 to R5, X, Y, A, B, m and n have the designations cited in the description - as inhibitors of the cyclin-dependent kinase. The invention also relates to methods for producing said derivatives and to th ...


3
Lücking Ulrich, Kettschau Georg, Briem Hans, Schwede Wolfgang, Schäfer Martina, Thierauch Karl Heinz, Husemann Manfred: Sulfoximine-pyrimidine macrocycles and the salts thereof , a process for making them, and their pharmaceutical use against cancer. Bayer Schering Pharma Aktiengesellschaft, Lücking Ulrich, Kettschau Georg, Briem Hans, Schwede Wolfgang, Schäfer Martina, Thierauch Karl Heinz, Husemann Manfred, BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, October 19, 2006: WO/2006/108695 (4 worldwide citation)

The invention relates to macrocyclic sulfoximines of the general Formula I : (I), wherein A, X, Y, R1, R2 and R3 have the meaning as given in the specification and the claims, and to salts thereof; to pharmaceutical compositions comprising the macrocyclic sulfoximines, and to a method of preparing t ...


4
Brumby Thomas, Jautelat Rolf, Prien Olaf, Schäfer Martina, Siemeister Gerhard, Lücking Ulrich, Huwe Christoph: (De) Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel, (En) Cdk inhibiting pyrimidines, production thereof and their use as medicaments. Schering Aktiengesellschaft, December 5, 2002: WO/2002/096888 (2 worldwide citation)

(EN) The invention relates to the pyrimidine derivatives of general formula (1), wherein R?1¿, R?2¿, X, A and B are defined as in the description, for use as inhibitors of the cyclin-dependent kinase. The invention further relates to the production thereof as well as to their use as medicament in th ...


5
Jautelat Rolf, Brumby Thomas, Prien Olaf, Schäfer Martina, Siemeister Gerd: (De) Lösliche cdk-inhibitorische indirubinderivate, (En) Soluble cdk-inhibitory indirubin derivatives. Schering Aktiengesellschafat, Jautelat Rolf, Brumby Thomas, Prien Olaf, Schäfer Martina, Siemeister Gerd, December 19, 2002: WO/2002/100401 (1 worldwide citation)

(EN) The invention relates to indirubin derivatives of formula (I) that, by establishing a basic side chain in the 5-position, contain a radically increased solubility with a simultaneous improvement in the biological activity. The invention also relates to intermediate products, to a method for the ...


6
FÜRSTNER Chantal, ACKERSTAFF Jens, STRAUB Alexander, MEIER Heinrich, TINEL Hanna, ZIMMERMANN Katja, TERSTEEGEN Adrian, ZUBOV Dimitry, KAST Raimund, SCHAMBERGER Jens, SCHÄFER Martina, BÖRNGEN Kirsten: [fr] URACILES À SUBSTITUTION BICYCLIQUE ET LEUR UTILISATION, [en] BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF, [de] BICYCLISCH-SUBSTITUIERTE URACILE UND IHRE VERWENDUNG. BAYER PHARMA AKTIENGESELLSCHAFT, BIP PATENTS, November 14, 2013: WO/2013/167495 (1 worldwide citation)

[de] Die vorliegende Anmeldung betrifft neue bicyclisch-substituierte Uracil-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung allein oder in Kombinationen zur Behandlung und/oder Prophylaxe von Krankheiten sowie ihre Verwendung zur Herstellung von Arzneimitteln zur Behandlung und/oder Proph ...


7
FÜRSTNER CHANTAL , ACKERSTAFF JENS , STRAUB ALEXANDER , MEIER HEINRICH , TINEL HANNA , ZIMMERMANN KATJA , TERSTEEGEN ADRIAN , ZUBOV DMITRY , KAST REIMUND , SCHAMBERGER JENS , SCHÄFER MARTINA , BÖRNGEN KIRSTEN : [de] BICYCLISCH-SUBSTITUIERTE URACILE UND IHRE VERWENDUNG, [en] BICYCLIC SUBSTITUTED URACILS AND THEIR USE, [fr] URACILE SUBSTITUE BICYCLIQUE ET SON UTILISATION. BAYER PHARMA  , July 20, 2016: EP3045456-A1

[de] Die vorliegende Anmeldung betrifft neue bicyclisch-substituierte Uracil-Derivate, ihre Verwendung allein oder in Kombinationen zur Behandlung und/oder Prophylaxe von peripheren Durchblutungsstörungen sowie ihre Verwendung zur Herstellung von Arzneimitteln zur Behandlung und/oder Prophylaxe von ...


8

9

10
Jautelat Rolf, Brumby Thomas, Prien Olaf, Schäfer Martina, Siemeister Gerhard: (De) Cdk-inhibitorische indirubinderivate mit erhöhter löslichkeit, (En) Cdk-inhibitory indirubin derivatives having an increased solubility. Schering Aktiengesellschaft, Jautelat Rolf, Brumby Thomas, Prien Olaf, Schäfer Martina, Siemeister Gerhard, September 26, 2002: WO/2002/074742

(EN) The invention relates to indirubin derivatives, which maintain a radically increased solubility while preserving the biological activity at the same time by establishing a quaternary center in the R?1¿ position. The invention also relates to the production of the indirubin derivatives, to their ...